Details for Patent: 7,635,773
✉ Email this page to a colleague
Summary for Patent: 7,635,773
Title: | Sulfoalkyl ether cyclodextrin compositions |
Abstract: | SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD composition comprises a sulfoalkyl ether cyclodextrin and less than 100 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length. |
Inventor(s): | Antle; Vincent (Olathe, KS) |
Assignee: | CyDex Pharmaceuticals, Inc. (Lenexa, KS) |
Application Number: | 12/404,174 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,635,773 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Use; Process; Compound; Device; |
Drugs Protected by US Patent 7,635,773
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-001 | Dec 24, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-002 | Nov 16, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Baxter Hlthcare | NEXTERONE | amiodarone hydrochloride | INJECTABLE;INJECTION | 022325-003 | Nov 16, 2010 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Melinta | BAXDELA | delafloxacin meglumine | POWDER;INTRAVENOUS | 208611-001 | Jun 19, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Lundbeck Pharms Llc | CARNEXIV | carbamazepine | SOLUTION;INTRAVENOUS | 206030-001 | Oct 7, 2016 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Lupin | SESQUIENT | fosphenytoin sodium | SOLUTION;INTRAVENOUS | 210864-001 | Nov 5, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Lupin | SESQUIENT | fosphenytoin sodium | SOLUTION;INTRAVENOUS | 210864-002 | Nov 5, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,635,773
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009241858 | ⤷ Sign Up | |||
Brazil | PI0905080 | ⤷ Sign Up | |||
Canada | 2702603 | ⤷ Sign Up | |||
Canada | 2771879 | ⤷ Sign Up | |||
China | 101959508 | ⤷ Sign Up | |||
China | 105288650 | ⤷ Sign Up | |||
China | 114053423 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |